Martian atmospheric lee waves

Mariner 9 television pictures of Mars extensive mountain lee wave phenomenon in the northern mid-latitudes during winter were evaluated. The characteristic wave length of the lee waves is readily observable, and in a few cases the boundaries of the wave patterns, as well as the wave length, are observed. The cloud patterns resulting from the waves generated by the flow across a mountain or crater are shown to be dependent upon the velocity profile of the air stream and the vertical stability of the atmosphere. Using the stability as inferred by the temperature structure obtained from the infrared spectrometer data, a two layer velocity model of the air stream is used in calculations based on the theory of mountain lee waves. Results yield magnitudes generally in agreement with various other circulation models

Polar symmetric flow of a viscous compressible atmosphere; an application to Mars

The atmosphere is assumed to be driven by a polar symmetric temperature field and the equations of motion in pressure ratio coordinates are linearized by considering the zero order in terms of a thermal Rossby number R delta I/(2a omega) sq where delta T is a measure of the latitudinal temperature gradient. When the eddy viscosity is greater than 1 million sq cm/sec, the boundary layer extends far up into the atmosphere, making the geostrophic approximation invalid for the bulk of the atmosphere. A temperature model for Mars was used which was based on Mariner 9 infrared spectral data with a 30% increase in the depth averaged temperature from the winter pole to the subsolar point. The results obtained for the increase in surface pressure from the subsolar point to the winter pole, as a function of eddy viscosity and with no-slip conditions imposed at the surface, are given

Effectiveness of a Multifactorial Cardiovascular Risk Reduction Clinic for Diabetes Patients with Depression

Introduction Depression may attenuate the effects of diabetes interventions. Our ongoing Cardiovascular Risk Reduction Clinic simultaneously addresses hyperglycemia, hypertension, smoking, and hyperlipidemia. We examined the relationship between depression diagnosis and responsiveness to the Cardiovascular Risk Reduction Clinic. Methods We studied Cardiovascular Risk Reduction Clinic participants with diabetes who had a depression diagnosis and those with no mental health diagnosis. Our outcome measure was change in 20-year cardiovascular mortality risk according to the United Kingdom Prospective Diabetes Study (UKPDS) score. Results Of 231 participants, 36 (15.6%) had a depression diagnosis. Participants with a depression diagnosis had a higher baseline UKPDS score (56.8 [SD 21.3]) than participants with no mental health diagnosis (49.5 [SD 18.7], P =.04). After Cardiovascular Risk Reduction Clinic participation, mean UKPDS scores did not differ significantly (37.8 [SD 15.9] for no mental health diagnosis and 39.4 [SD 18.6] for depression diagnosis). Mean UKPDS score reduction was 11.6 [SD 15.6] for no mental health diagnosis compared with 18.4 [SD 15.9] for depression diagnosis (P =.03). Multivariable linear regression that controlled for baseline creatinine, number of Cardiovascular Risk Reduction Clinic visits, sex, and history of congestive heart failure showed significantly greater improvement in UKPDS score among participants with a depression diagnosis (ß = 6.0, P =.04) and those with more Cardiovascular Risk Reduction Clinic visits (ß = 2.1, P \u3c.001). Conclusion The Cardiovascular Risk Reduction Clinic program reduced cardiovascular disease risk among patients with diabetes and a diagnosis of depression. Further work should examine how depressive symptom burden and treatment modify the effect of this collaborative multifactorial program and should attempt to determine the durability of the effect

Spatially variable hydrologic impact and biomass production tradeoffs associated with Eucalyptus (E. grandis) cultivation for biofuel production in Entre Rios, Argentina

Climate change and energy security promote using renewable sources of energy such as biofuels. High woody biomass production achieved from short-rotation intensive plantations is a strategy that is increasing in many parts of the world. However, broad expansion of bioenergy feedstock production may have significant environmental consequences. This study investigates the watershed-scale hydrological impacts of Eucalyptus (E. grandis) plantations for energy production in a humid subtropical watershed in Entre Rios province, Argentina. A Soil and Water Assessment Tool (SWAT) model was calibrated and validated for streamflow, leaf area index (LAI), and biomass production cycles. The model was used to simulate various Eucalyptus plantation scenarios that followed physically based rules for land use conversion (in various extents and locations in the watershed) to study hydrological effects, biomass production, and the green water footprint of energy production. SWAT simulations indicated that the most limiting factor for plant growth was shallow soils causing seasonal water stress. This resulted in a wide range of biomass productivity throughout the watershed. An optimization algorithm was developed to find the best location for Eucalyptus development regarding highest productivity with least water impact. E. grandis plantations had higher evapotranspiration rates compared to existing terrestrial land cover classes; therefore, intensive land use conversion to E. grandis caused a decline in streamflow, with January through March being the most affected months. October was the least-affected month hydrologically, since high rainfall rates overcame the canopy interception and higher ET rates of E. grandis in this month. Results indicate that, on average, producing 1 kg of biomass in this region uses 0.8 m of water, and the green water footprint of producing 1 m fuel is approximately 2150 m water, or 57 m water per GJ of energy, which is lower than reported values for wood-based ethanol, sugar cane ethanol, and soybean biodiesel

Clinical and Epidemiological Study on Tubercular Uveitis in a Tertiary Eye Care Centre in Italy

PURPOSE: To describe frequency, clinical characteristics, and visual prognosis of tubercular uveitis (TBU) in a nonendemic country. METHODS: We retrospectively reviewed 3743 charts of patients with endogenous uveitis visited from 2008 to 2018 at a tertiary referral centre in Rome, Italy. We included immunocompetent patients with diagnosis of TBU. Patients were divided in two groups: patients with history of uveitis without a previous diagnosis of TBU (group A) and patients at their first episode of TB uveitis (group B). RESULTS: TBU was diagnosed in 28 (0.75%) out of 3743 patients. Twelve (42.9%) patients came from tuberculosis endemic areas. All patients received specific antitubercular treatment (ATT) and were evaluated for a mean follow-up of 3.2 ± 2.9 years. Group A showed a greater number of ocular complications when compared with group B. ATT was effective in reducing the frequency of recurrences of uveitis in patients of group B. CONCLUSION: Intraocular inflammation can be the first manifestation of tuberculosis. Our data highlight that early diagnosis and specific treatment of TBU may allow to decrease recurrences and to improve visual outcomes

A controlled trial of Partners in Dementia Care: veteran outcomes after six and twelve months

Introduction: “Partners in Dementia Care” (PDC) tested the effectiveness of a care-coordination program integrating healthcare and community services and supporting veterans with dementia and their caregivers. Delivered via partnerships between Veterans Affairs medical centers and Alzheimer’s Association chapters, PDC targeted both patients and caregivers, distinguishing it from many non-pharmacological interventions. Hypotheses posited PDC would improve five veteran self-reported outcomes: 1) unmet need, 2) embarrassment about memory problems, 3) isolation, 4) relationship strain and 5) depression. Greater impact was expected for more impaired veterans. A unique feature was self-reported research data collected from veterans with dementia. Methods and Findings: Five matched communities were study sites. Two randomly selected sites received PDC for 12 months; comparison sites received usual care. Three structured telephone interviews were completed every 6 months with veterans who could participate. Results: Of 508 consenting veterans, 333 (65.6%) completed baseline interviews. Among those who completed baseline interviews, 263 (79.0%) completed 6-month follow-ups and 194 (58.3%) completed 12-month follow-ups. Regression analyses showed PDC veterans had significantly less adverse outcomes than those receiving usual care, particularly for more impaired veterans after 6 months, including reduced relationship strain (B = −0.09; p = 0.05), depression (B = −0.10; p = 0.03), and unmet need (B = −0.28; p = 0.02; and B = −0.52; p = 0.08). PDC veterans also had less embarrassment about memory problems (B = −0.24; p = 0.08). At 12 months, more impaired veterans had further reductions in unmet need (B = −0.96; p < 0.01) and embarrassment (B = −0.05; p = 0.02). Limitations included use of matched comparison sites rather than within-site randomization and lack of consideration for variation within the PDC group in amounts and types of assistance provided. Conclusions: Partnerships between community and health organizations have the potential to meet the dementia-related needs and improve the psychosocial functioning of persons with dementia. Trial Registry NCT0029116

Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial

<p>Abstract</p> <p>Background</p> <p>Depression is prevalent in people with type 2 diabetes and affects both glycaemic control and overall quality of life. The aim of this investigator-initiated trial was to evaluate the effect of the antidepressant paroxetine on quality of life, metabolic control, and mental well-being in mildly depressed diabetics aged 50–70 years.</p> <p>Methods</p> <p>We randomised 49 mildly depressed primary care outpatients with non-optimally controlled diabetes to a 6-month double-blind treatment with either paroxetine 20 mg per day or matching placebo. Primary efficacy measurements were quality of life and glycaemic control. The primary global outcome of the study was defined as a 10 points improvement in the SF-36 quality of life score. The primary metabolic outcome of the study was defined as a 0.8%-units decrease in glycosylated haemoglobin A_1c(GHbA_1c). Psychiatric symptoms were assessed with the Hospital Anxiety and Depression Scale.</p> <p>Results</p> <p>Six patients withdrew their consent before starting medication and six dropped out later in the study. We performed analysis of covariance with the baseline value as a covariate. Quality of life and glycaemic control as well as symptoms of depression and anxiety improved in both groups over the 6-month study period. After three months of treatment we found a statistically significant difference between the two treatment groups in GHbA_1c(mean difference = 0.59%-units, p = 0.018) and in SF-36 score (mean difference = 11.0 points, p = 0.039). However, at the end of the study, no statistically significant differences between the treatment groups were observed. No severe adverse events occurred.</p> <p>Conclusion</p> <p>This pragmatic study of primary care patients did not confirm earlier preliminary findings indicating a beneficial effect of paroxetine on glycaemic control. The study indicates that in pragmatic circumstances any possible benefit from administration of paroxetine in diabetic patients with sub-threshold depression is likely to be modest and of short duration. Routine antidepressant prescription for patients with diabetes and sub-threshold depressive symptoms is not indicated.</p> <p>Trial registration</p> <p>Current controlled trials ISRCTN55819922</p

Use of antidepressant medications in relation to the incidence of breast cancer

Although associations have been reported between antidepressant use and risk of breast cancer, the findings have been inconsistent. We conducted a population-based case–control study among women enrolled in Group Health Cooperative (GHC), a health maintenance organization in Washington State. Women with a first primary breast cancer diagnosed between 1990 and 2001 were identified (N=2904) and five controls were selected for each case (N=14396). Information on antidepressant use was ascertained through the GHC pharmacy database and on breast cancer risk factors and screening mammograms from GHC records. Prior to one year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio=1.06, 95% CI 0.94–1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR=0.98, 95% CI 0.80–1.18). There also were no differences between cases and controls with regard to the number of prescriptions filled or the timing of use. Taken as a whole, the results from this and other studies to date do not indicate an altered risk of breast cancer associated with the use of antidepressants overall, by class, or for individual antidepressants